Dr Adam Ritchie

Contact information

Email
adam.ritchie@ndm.ox.ac.uk

Telephone
01865 617623

Address
Old Road Campus Research Build (ORCRB), Roosevelt Drive, Oxford OX3 7DQ

Research groups

Adam Ritchie

BSc, PhD, FHEA

Senior Vaccinologist

Douglas Group

Adam is a Senior Vaccinologist at the Jenner Institute. He is currently focused on the rabies, EBV and COVID-19 vaccine projects, alongside work on policy and regulation as part of Vax-Hub Global. Adam's interest is on translation of academic research into real world impact through the efficient development, manufacture, and clinical testing of vaccine candidates.

Adam works includes the design and delivery of early phase clinical trials, regulatory affairs, public policy, and vaccine manufacturing.

Adam is also a Lecturer in Human Science at St Catherine's College.

Key publications

Tetraspanin-based immunocapture for high-depth proteomic profiling of extracellular vesicles from cerebrospinal fluid for biomarker discovery

Dellar ER. et al, (2026), Clinical Proteomics, 23

Perceptions of death, dying and the body in Vietnamese culture: A qualitative exploration from a study examining the potentials of minimally invasive tissue sampling in Vietnam

Doan NP. et al, (2026), SSM - Qualitative Research in Health, 9, 100714 - 100714

Ensuring vaccine cold chain integrity: A rapid and low-cost test for identifying heat-exposed sucrose-containing vaccines

Arman BY. et al, (2026), International Journal of Pharmaceutics: X, 11, 100467 - 100467

Advancing the concept of community positive health through participatory research in marginalized communities in Kenya

Peters LER. et al, (2026), Social Science & Medicine, 398, 119147 - 119147

Rickettsial seropositivity in Lao PDR smallholder livestock farms: Implications for animal and human health.

Tawfik C. et al, (2026), One health (Amsterdam, Netherlands), 22

Trends in pneumothorax mortality in England (2004–2023): a population-based observational study

Zhong X. et al, (2026), The Lancet Regional Health - Europe, 64, 101632 - 101632

The normalisation of under-resourcing limits the potential for improvement of critical care: evidence from a multi-method study of Kenyan hospitals

McKnight J. et al, (2026), Social Science & Medicine, 396, 118843 - 118843

Deformation-Recovery diffusion model (DRDM): Instance deformation for image manipulation and synthesis

Zheng J-Q. et al, (2026), Medical Image Analysis, 110, 103987 - 103987

Prospects and perils of antimicrobial resistance cluster detection using routinely collected data: an illustration from tertiary hospitals in Thailand representing different data contexts

Rangsiwutisak C. et al, (2026), Journal of Hospital Infection, 170, 48 - 59

Acute upper gastrointestinal bleeding in the UK: 2022 audit update

Nigam GB. et al, (2026), Gut, 75, 760 - 771

Toward Integration of Molecular Measures and Artificial Intelligence-Based Assessments With Clinical End Points in Inflammatory Bowel Disease

Reinisch W. et al, (2026), Gastroenterology, 170, 686 - 703

Age distribution of respiratory syncytial virus disease in children younger than 5 years in low-income and middle-income countries: a systematic review and meta-analysis

Mahmud S. et al, (2026), The Lancet Child & Adolescent Health, 10, 245 - 254

Chronic Malaria Is Associated With Trauma-related Splenic Rupture Requiring Splenectomy

Shanti PAI. et al, (2026), The Journal of Infectious Diseases, 233, e740 - e744

Assessing the innovation competency and entrepreneurial capacity of health students in Vietnam: a cross-sectional study

Le ANT. et al, (2026), BMC Medical Education

Identification of transporters essential for survival of Leishmania promastigotes in the digestive tract of sand flies

Sádlová J. et al, (2026), PLOS Pathogens, 22, e1014049 - e1014049

Dopamine release from Parkinson's patient-derived neurons is disrupted due to impaired synaptic vesicle loading

Cramb KML. et al, (2026)

Development and Evaluation of Compact Semi-Synthetic Promoters for Enhanced Antigen Expression in Adenoviral-Vectored Vaccines

Hlaváč M. et al, (2026), Vaccines, 14, 260 - 260

Cochrane Database of Systematic Reviews

(2026)

Chromosomal instability shapes the tumor microenvironment of esophageal adenocarcinoma via a cGAS–chemokine–myeloid axis

Beernaert B. et al, (2026), Science Advances, 12

Biosafety and biosecurity for Burkholderia pseudomallei and Burkholderia mallei : evidence, gaps, and sustainable practice in endemic, low-resource settings

Blacksell SD. et al, (2026), Clinical Microbiology Reviews

Ubiquitin E3 ligase KLHL6 brings exhausted T-cells back into action

Chen Z. et al, (2026), Immunity & Inflammation, 2

Estimating the changing prevalence of molecular markers of artemisinin partial resistance in Plasmodium falciparum malaria in Sub-Saharan Africa

Harrison LE. et al, (2026)

Longitudinal Epidemiology and Variant Dynamics of SARS-CoV-2 in Coastal Kenya (2020–2025): Clinical Features and Wave Patterns

Lambisia AW. et al, (2026), Open Forum Infectious Diseases, 13

Nasopharyngeal Microbiome Composition and its Clinical Correlates in Children Hospitalized with Severe Pneumonia in East Africa.

Makori TO. et al, (2026), J Infect Dis

ESR1 Mutation in Endocrine Treatment-Naïve Endometrial Cancer: Prevalence, Characteristics, and Prognostic Implications, Results from the UTOLA Phase II GINECO Trial

Blanc-Durand F. et al, (2026), Clinical Cancer Research, 32, 963 - 969

Data from ESR1 Mutation in Endocrine Treatment-Naïve Endometrial Cancer: Prevalence, Characteristics, and Prognostic Implications, Results from the UTOLA Phase II GINECO Trial

Blanc-Durand F. et al, (2026)

Supplementary Table S1 from ESR1 Mutation in Endocrine Treatment-Naïve Endometrial Cancer: Prevalence, Characteristics, and Prognostic Implications, Results from the UTOLA Phase II GINECO Trial

Blanc-Durand F. et al, (2026)

Impact of an electronic clinical decision support algorithm (eCDSA) on antibiotic prescribing in primary care in Cambodia: A cluster randomised controlled trial

Wynberg E. et al, (2026), International Journal of Infectious Diseases, 164, 108382 - 108382

HepB-boost: Implementation of free-of-charge health care worker hepatitis B testing and vaccination at Kilifi County Referral Hospital, Kenya

Downs LO. et al, (2026), International Journal of Infectious Diseases, 164, 108418 - 108418

British Society of Gastroenterology guidelines on colorectal surveillance in inflammatory bowel disease

East JE. et al, (2026), Gut, 75, 442 - 475

Addressing pandemic-wide systematic errors in the SARS-CoV-2 phylogeny

Hunt M. et al, (2026), Nature Methods, 23, 653 - 662

Vaccine effectiveness of a bivalent respiratory syncytial virus (RSV) pre-F vaccine against RSV-associated hospital admission among adults aged 75–79 years in England: a multicentre, test-negative, case–control study

Symes R. et al, (2026), The Lancet Infectious Diseases, 26, 229 - 238

(Un)intended consequences: a social sciences stocktake of a decade of Global Action Plan-inspired antimicrobial governance

Kirchhelle C. et al, (2026), The Lancet Microbe, 7, 101315 - 101315

Protocol for stable cell line production to express muscle-type nicotinic receptor

Li A. et al, (2026), STAR Protocols, 7, 104427 - 104427

The potential of a centrally implemented system for national surveillance of bloodstream infections in England, compared to current local surveillance, 2023–2024

Cregan J. et al, (2026), Journal of Hospital Infection, 169, 5 - 14

Intratumoral heterogeneity and immunotherapy resistance: clinical implications

Keenan BP. et al, (2026), Annals of Oncology, 37, 314 - 328

Data reuse in global health: perspectives from actors in policy, funding and research

Waithira N. et al, (2026), BMJ Global Health, 11, e021974 - e021974

The Role of Fibroblast–Epithelial Cross-Talk on the Distribution of Distinct Fibroblast Phenotypes in the Intestinal Crypt

Atkinson G. et al, (2026), Bulletin of Mathematical Biology, 88

Data reuse in global health: perspectives from actors in policy, funding and research

Waithira N. et al, (2026), BMJ Global Health, 11, e021974 - e021974

HepB-boost: Implementation of free-of-charge health care worker hepatitis B testing and vaccination at Kilifi County Referral Hospital, Kenya

Downs LO. et al, (2026), International Journal of Infectious Diseases, 164, 108418 - 108418

Intratumoral heterogeneity and immunotherapy resistance: clinical implications

Keenan BP. et al, (2026), Annals of Oncology, 37, 314 - 328

(Un)intended consequences: a social sciences stocktake of a decade of Global Action Plan-inspired antimicrobial governance

Kirchhelle C. et al, (2026), The Lancet Microbe, 7, 101315 - 101315

Exploring layers of vulnerability during COVID-19: qualitative research with communities in Indonesia, Nepal, and Vietnam.

Tran TP. et al, (2026), BMC medical ethics

Evaluation of the Bangkok Health Research and Ethics Interest Group: reflecting on the experiences of group members, researchers and facilitators participating in an urban community advisory board in Thailand.

Osterrieder A. et al, (2026), Research involvement and engagement, 12

Applying WHO Prioritization Criteria for Moderate Wasting: Programmatic Implications.

Potani I. et al, (2026), Maternal & child nutrition, 22

Impact of switching from manual to automated aerobic blood culture on bacteremia diagnosis in Lao PDR.

Jaksuwan R. et al, (2026), Microbiology spectrum

The age-specific concentrations and seroprevalence of antibodies against Salmonella Enteritidis (O:9) and Salmonella Typhimurium (O:4,5) across three sites in Kenya.

Muthumbi EM. et al, (2026), The Journal of infectious diseases

Leptospirosis Incidence at Four Sites in Sub-Saharan Africa and South East Asia: An International Multi-Site Hybrid Surveillance Study.

Crump JA. et al, (2026), Open forum infectious diseases, 13

TCR T cells targeting IgA- and IgG-expressing multiple myeloma.

Douvlataniotis K. et al, (2026), Blood

Patterns of HIV-1 viral load suppression and drug resistance during the dolutegravir transition: a population-based longitudinal study.

Martin MA. et al, (2026), Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Family Member and Healthcare Provider Perceptions of Factors Influencing Undernutrition Among Infants and Young Children in South Asia: A Systematic Review of Qualitative Studies

Uddin MF. et al, (2026), Nutrients, 18, 776 - 776

Comparison of CD4 T cell response in Plasmodium falciparum and vivax malaria

Nalubega M. et al, (2026), The Journal of Infectious Diseases

Correction: Grant et al. Low pH, High Stakes: A Narrative Review Exploring the Acid-Sensing GPR65 Pathway as a Novel Approach in Renal Cell Carcinoma. Cancers 2025, 17, 3883

Grant M. et al, (2026), Cancers, 18, 760 - 760

Nanopore long-read-only genome assembly of clinical Enterobacterales isolates is complete and accurate

Nagy D. et al, (2026), Microbial Genomics, 12

Recent publications

Routine childhood rabies pre-exposure prophylaxis can be cost effective in low- and middle-income countries.

Ritchie AJ. et al, (2025), Vaccine, 47

Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial

Madhavan M. et al, (2022), eBioMedicine, 85, 104298 - 104298

Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trial

Jenkin D. et al, (2022), The Lancet Microbe, 3, e663 - e671

Manufacturing a chimpanzee adenovirus-vectored SARS-CoV-2 vaccine to meet global needs.

Joe CCD. et al, (2022), Biotechnology and bioengineering, 119, 48 - 58

Publisher Correction: Characterisation of factors contributing to the performance of nonwoven fibrous matrices as substrates for adenovirus vectored vaccine stabilisation.

Dulal P. et al, (2021), Scientific reports, 11

Characterisation of factors contributing to the performance of nonwoven fibrous matrices as substrates for adenovirus vectored vaccine stabilisation.

Dulal P. et al, (2021), Scientific reports, 11

Making THE vaccine

Joe CCD. and Ritchie AJ., (2021), Biochemist, 43, 8 - 13

Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

Ewer KJ. et al, (2021), Nature Medicine, 27, 1116 - 1116

Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Barrett JR. et al, (2021), Nature Medicine, 27, 1113 - 1113

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Voysey M. et al, (2021), The Lancet, 397, 881 - 891

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Barrett JR. et al, (2021), Nature Medicine, 27, 279 - 288

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

Ewer KJ. et al, (2021), Nature Medicine, 27, 270 - 278

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Voysey M. et al, (2021), The Lancet, 397, 99 - 111

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Ramasamy MN. et al, (2020), The Lancet, 396, 1979 - 1993

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Folegatti PM. et al, (2020), The Lancet, 396, 467 - 478

Characterisation of factors contributing to the performance of nonwoven fibrous matrices as substrates for adenovirus vectored vaccine stabilisation

Dulal P. et al, (2020)

Simian adenovirus vector production for early-phase clinical trials: A simple method applicable to multiple serotypes and using entirely disposable product-contact components

Fedosyuk S. et al, (2019), Vaccine, 37, 6951 - 6961